Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ferricitras in preparation of medicine to prevent and treat angiosteosis

A technology of vascular calcification and ferric citrate, which is applied in drug combinations, cardiovascular system diseases, and pharmaceutical formulations, etc.

Active Publication Date: 2010-09-15
苏荣仁
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since cardiovascular calcification also exists in patients with chronic kidney disease, it is believed that hyperphosphatemia is an influencing factor for cardiovascular calcification in patients with ESRD (end-stage renal failure), and hyperphosphatemia is involved in vascular ectopic calcification in ESRD. However, experiments have shown that blood phosphorus and blood calcium in some ESRD patients with vascular calcification are still normal. In addition, vascular calcification associated with atherosclerosis has no direct relationship with human blood phosphorus levels.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ferricitras in preparation of medicine to prevent and treat angiosteosis
  • Application of ferricitras in preparation of medicine to prevent and treat angiosteosis
  • Application of ferricitras in preparation of medicine to prevent and treat angiosteosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0138] Embodiment 1: the preparation of ferric citrate

[0139] Referring to the preparation method recorded in the "Food Additive Handbook" Chemical Industry Press, ferric citrate was prepared by reacting ferric hydroxide with citric acid.

[0140] Weigh 106.9g of micronized ferric hydroxide and 220.7g of citric acid monohydrate, put them in a stirred flask, add 1000ml of water, heat to 60°C in a water bath, and continue to stir for 72 hours. To judge the end point of the reaction, absorb 1ml Add 10ml of water to the supernatant, and detect with spectrophotometry, the solution is basically clear and reaches the end of the reaction.

[0141] The reaction solution was concentrated below 60°C until the relative density of the solution was 1.26 to obtain a brown viscous concentrated solution.

[0142] The concentrated solution was dried under reduced pressure below 60°C to obtain 307 g of crude ferric citrate.

[0143] Put the above-mentioned ferric citrate in a beaker, add 300...

Embodiment 2

[0144] Embodiment 2: Acute toxicity test of ferric citrate mice

[0145] On the basis of the pre-test, 70 Kunming mice (19-21 g, half male and half male) were randomly divided into 7 groups after fasting for 15 hours, with 10 mice in each group. With 4% starch paste, the iron citrate prepared in Example 1 was formulated into uniform suspensions of 7 concentrations, and 7 dosage groups were set up, and the dosages from high to low were: 10.00, 8.00, 6.40, 5.12, 4.10, 3.28 and 2.62 g / kg. The mice were given intragastric administration at 20ml / kg respectively, and the animal's activities, food intake, skin, mucous membranes, feces and death were observed and recorded immediately after the administration, and observed at least once a day within two weeks after the administration. Autopsies were performed on the dead animals, and the changes of various tissues and organs were observed. The median lethal dose was calculated by Bliss method. The results are shown in Table 8 below;...

Embodiment 3

[0160] Embodiment 3: the research of ferric citrate treatment arterial calcification

[0161] The ferric citrate prepared in Example 1 was made into a suspension with 4% starch solution, and administered by intragastric administration according to different dosages.

[0162] Experimental method According to the method of Niederhoffer, an animal model of vascular calcification in rats was prepared.

[0163] 54 male SD rats, weighing 150-180g, were randomly divided into 5 groups: (1) Vascular calcification group (VDN) (n=12): intramuscular injection of vitamin D to the rats at 9:00 on the first day of the experiment 3 (3×10 5 U / kg) and nicotine dissolved in soybean oil (25mg / kg, 5ml / kg) were administered orally, and nicotine was repeatedly administered once at 18:00. Stomach, for 4 consecutive weeks; (2) Blank control group (control, n=10): given intramuscular injection of the same amount of soybean oil, or intragastric administration of simple soybean oil instead of vitamin D...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the application of ferric citrate in preparing medicine for preventing and treating calcification of blood vessel. The present invention has determined curative effect. Experiment proves that ferric citrate can intervene calcification of blood vessel and inhibit calcification effectively, and may reverse calcification of blood vessel.

Description

technical field [0001] The present invention relates to the field of vascular calcification, and relates to the application of ferric citrate in the prevention and treatment of vascular calcification, in particular to the research field of prevention and treatment of cardiovascular ectopic calcification, specifically, the application of ferric citrate in the prevention and treatment of cardiovascular ectopic calcification Applications. Background technique [0002] Vascular calcification (also known as ectopic calcification of the cardiovascular system) is a pathological change closely related to clinical cardiovascular diseases. It mainly occurs in arterial vessel walls and heart valves. It is closely related to diabetes and end-stage renal disease, and can increase the occurrence of serious clinical events such as acute myocardial infarction, ischemic attack of peripheral vascular disease, and intimal tear after angioplasty, and is a predictor of cardiovascular disease inc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/194A61P3/10A61P9/00A61P9/10A61P13/12A61P39/06
Inventor 苏荣仁
Owner 苏荣仁
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com